OSTEOPOROSIS DISEASE ENROLLMENT FORM

PATIENT INFORMATION

Ď	C	:(J	3	2	В	3	S	3)	E
-														
·	IN	FI	U	SI	C	1	Į.	S	E	R	V	I	3	E

PATIENT INSURANCE INFORMATION

Last Name	First N	lame	Primary Medical Insuran	ce Medical Ins	Medical Insurance Phone				
Social Security No	Date o	f Birth	Subscriber Name						
Sex □ M □ F Weight	Height		Rx Card (PBM)	Group No	Group No				
Llama Dhama) M	4-1-1-	Prescription Card Bin #	PCN #					
Home Phone	Work/N	doblie	TREATMENT ARRANGEMENTS						
Home Address			•Start Date: Ship Meds □ Home □ Doctor's Office						
City	State	Zip		Office Other:					
STATEMENT OF	MEDICAL NECESSITY								
Diagnosis (ICD-10 CODE): M81.0 Osteoporosis M80.0 Osteoporosis with fracture Date of Diagnosis:									
Is patient using prescribed therapy in combination with other biologics for MS? IS patient pregnant, Nursing, Or Planning pregnancy? IS patient pregnant, Nursing, Or Planning pregnant, Nursing, Nursing pregnant, Nursing									
Patient Evaluation: Does the patient have any of the following conditions? Unexplained elevations of alkaline phosphatase Yes No Allergies: Kegs/lbs Open epiphysis (i.e., pediatric or young adult patient) Yes No Patient Weight : Kegs/lbs Prior radiation therapy involving the skeleton Yes No Patient Weight : Kegs/lbs Bone metastases Yes No Patient Heights : Kegs/lbs Metabolic bone disease other than osteoporosis Yes No Pre - existing hypercalcemia Yes No Is the patient currently taking a bisphosphonate? Yes No If Yes to previous question, will current bisphosphonate therapy be discontinued upon induction Forteo® or Tymlos® Yes No For patients continuing Forteo® therapy, how long have they been taking Forteo® or Tymlos® Months Does the patient have hypocalcemia? Yes No Will the patient be supplemented with calcium and vitamin D? Yes No									
Bone Mineral Density Result: Fracture History:									
Prior (Failed) Medica	itions:								
Medication Strength Duration of Treatment/Reason for Discontinuation									
		_							
		PRESCRIPTIO	N INFORMATION						
MEDICATION	STRENGTH	DIF	RECTIONS	QUANTITY	REFILL				
□ EVENITY®	□ 210mg	☐ Inject 210mg SubQ Or	nce every month.						
□ BONIVA®	□ 3mg/3ml	□ Inject 3mg IV every 3	months.						
□ TYMLOS®	□ 3120mcg/1.56ml	□ Inject 80mcg SubQ on	ce daily.	30days					
□ PEN NEEDLES	31 gauge 5mm 6mm 8mm	Use with Tymlos® Delive	ery Device daily.	☐ 1 Device(4-week supply) ☐ 3 Devices (12– week supply) 1 Box (100ct)					
□ FORTEO®	□ 600mcg/2.4ml Device	□ Inject 20mcg (0.08ml)	SubQ once daily.	☐ 1 Device(4-week supply) ☐ 3 Devices (12— week supply)					
□ PEN NEEDLES	31 gauge 5mm 6mm 8mm Use with Forteo® December 1.5 or 1.5		ry Device daily.	1 Box (100ct)					
□ PROLIA®	☐ 1 single use Prefilled Syringe	☐ Inject 60mg SubQ eve	ry 6 months.						
□ RECLAST®	□ 5mg	☐ Infuse 5mg IV once a	year.	□ 1 Vial					
									
Physician Signature	: X	•	□ DAW (Dis	pense as Written) Date:					
Physician Name:			Fax:	•	Office Contact:				
Physician Address:	Thone.		NPI:	DEA:					
, siciaii Audi C33.			141 1.						

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake. Then destroy this document. Please direct all verification or notification to the above mentioned physician's office.

X By Signing this prescription & using Curbside's services, you are authorizing Curbside to contact insurance companies for prior authorizations on behalf of your practice.